via english.farsnews.com
A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University found
The drug, commonly used to treat epilepsy, calms hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a clinically recognized condition in which memory impairment is greater than expected for a person’s age and which greatly increases risk for Alzheimer’s dementia, according to the study published this week in NeuroImage: Clinical.
The findings validate the Johns Hopkins team’s initial conclusions, published three years ago in the journal Neuron. They also closely match the results in animal studies performed by the team and scientists elsewhere. Next, neuroscientist Michela Gallagher, the lead investigator, hopes the therapy will be tested in a large-scale, longer-term clinical trial.
Hippocampal over-activity is well-documented in patients with aMCI and its occurrence predicts further cognitive decline and progression to Alzheimer’s dementia, Gallagher said.
“What we’ve shown is that very low doses of the atypical antiepileptic levetiracetam reduces this over-activity,” Gallagher said. “At the same time, it improves memory performance on a task that depends on the hippocampus.”
The team studied 84 subjects — 17 of them were normal healthy aged participants and the rest had the symptoms of pre-dementia memory loss defined as aMCI. Everyone was over 55 years old, with an average age of about 70.
The subjects were given varying doses of the drug and also a placebo in a double-blind randomized trial. Researchers found low doses both improved memory performance and normalized the over-activity detected by functional magnetic resonance imaging that measures brain activity during a memory task. The ideal dosing found in this clinical study matched earlier preclinical studies in animal models.
“What we want to discover now, is whether treatment over a longer time will prevent further cognitive decline and delay or stop progression to Alzheimer’s dementia,” Gallagher said.
Read more: Drug Restores Brain Function and Memory in Early Alzheimer’s Disease
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
- New study finds ultrasound stimulation as effective therapy for Alzheimer's diseaseon January 26, 2022 at 1:21 am
An increase in average life expectancy in many parts of the world has made certain age-related diseases more common Alzheimer disease AD is one of them b ...
- Be well informed on new Alzheimer’s drugon January 26, 2022 at 1:00 am
Aduhelm (aducanumab) just approved by the FDA for Alzheimer’s disease was timely and important (“Medicare needs to test the new Alzheimer’s drug before paying”). As a retired geriatrician, with a ...
- Alzheimer's disease: An alternative hypothesis based on synaptic alterationson January 25, 2022 at 7:14 am
New research published today in Alzheimer's & Dementia, the journal of the Alzheimer's Association could explain why neurons fail to communicate effectively in people with Alzheimer's disease (AD).
- Two small biotechs hope that gene therapy will be the future of Alzheimer’s disease treatment. Here’s what we know so far.on January 25, 2022 at 5:30 am
Biotechs Lexeo Therapeutics and Shape Therapeutics gave the public its first look at the one-and-done gene therapies they're creating for Alzheimer's.
- Transcranial ultrasound used in mice with Alzheimer's disease featureson January 25, 2022 at 4:45 am
In December 2021 scientists from South Korea used a technology called transcranial ultrasound stimulation to excite specific areas of mice brain. They found mice with features of Alzheimer's had ...
- CMS severely limits coverage of Alzheimer's treatment: What it means for people living with the diseaseon January 24, 2022 at 1:34 pm
The Alzheimer's Association is calling on CMS to reverse a draft decision that would only provide coverage of a new drug for patients in clinical trials.
- The Alzheimer’s Death Panelon January 23, 2022 at 1:16 pm
The real reason Medicare won’t pay for a promising treatment.
- Urge broader coverage for Alzheimer’s disease drug | Letterson January 23, 2022 at 12:34 pm
The Centers for Medicare & Medicaid Services (CMS) has released its draft decision on whether Medicare will cover drugs containing monoclonal antibodies targeting amyloid for the treatment of ...
- The Powerful Case for Redefining Alzheimer’s Diseaseon January 23, 2022 at 4:20 am
The signature case of Alzheimer’s disease was a German woman named Auguste whose mental status began to deteriorate to the extent that her husband brought her to a psychiatry clinic in Frankfurt. She ...
- New Method for Treating Alzheimer’s Disease Developed by Researcherson January 20, 2022 at 7:20 am
Researchers at the University of Oslo have discovered a new way of treating Alzheimer's disease using artificial intelligence.
via Bing News
